| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥20588.3B | ¥20676.0B | -0.4% |
| Operating Income | ¥1274.7B | ¥1258.3B | +1.3% |
| Profit Before Tax | ¥1247.6B | ¥-500.5B | -0.6% |
| Net Income | ¥794.7B | ¥-779.2B | +13.2% |
| ROE | 4.6% | -4.7% | - |
FY2025 full year results: Revenue 2,058.8 billion yen (YoY -0.4%), Operating Income 127.5 billion yen (+1.3%), Ordinary Income 120.9 billion yen (+28.2%), Net Income attributable to owners 69.2 billion yen (returning to profitability from prior year loss of -77.9 billion yen). Revenue remained essentially flat while operating profit showed marginal improvement. The significant expansion in ordinary income of +26.6 billion yen was driven by improved financial income and other non-operating items. The company recovered to profitability with net income of 69.2 billion yen compared to a prior year loss of -77.9 billion yen, primarily due to the absence of the large-scale impairment loss of approximately 124.8 billion yen recorded in Life Sciences segment in the previous year. Operating margin held steady at approximately 6.2%, while ROE improved to 4.7% from negative territory.
Revenue decreased by 8.8 billion yen (-0.4%) to 2,058.8 billion yen, reflecting mixed segment performance. Automotive segment revenue increased by 21.8 billion yen driven by improved product mix and pricing policy effects. Electronics segment declined by 9.5 billion yen due to reduced shipments of EUV photomask blanks and withdrawal from chemically strengthened specialty glass business. Chemicals segment decreased by 9.4 billion yen primarily from lower PVC resin prices and weaker Southeast Asian market conditions. Life Sciences segment declined by 8.1 billion yen due to absence of prior year one-time income from bio-pharmaceutical business and increased fixed costs from European capacity expansion. Architectural Glass remained relatively stable with a 3.2 billion yen increase.
Operating profit increased by 1.6 billion yen (+1.3%) to 127.5 billion yen. The primary driver was Automotive segment, which contributed a 15.3 billion yen increase through improved product mix, pricing strategies, and cost optimization, achieving ROCE exceeding 10%. Electronics segment declined by 6.9 billion yen due to lower EUV blanks shipments and withdrawal costs from specialty glass business. Chemicals segment decreased by 3.7 billion yen from lower PVC prices and maintenance cost increases. Life Sciences segment operating loss widened by 1.1 billion yen to -22.3 billion yen, though improvement is expected as CDMO capacity expansions come online.
The gap between operating income (127.5 billion yen) and ordinary income (120.9 billion yen) of -6.6 billion yen reflects net financial costs, though the gap narrowed significantly from prior year's -31.6 billion yen. The substantial improvement in ordinary income (+28.2%) compared to operating income (+1.3%) indicates enhanced non-operating profitability.
Net income attributable to owners of 69.2 billion yen represents a return to profitability from prior year loss of -77.9 billion yen, an improvement of 147.1 billion yen. This was primarily driven by the non-recurring effect of prior year's large-scale impairment loss (approximately 124.8 billion yen in Life Sciences). The tax burden coefficient of 0.554 indicates an effective tax rate of approximately 36.3%, which constrains net income growth.
Performance pattern: Revenue flat/Profit up. Revenue remained essentially unchanged while operating profit improved marginally. The return to net profitability was significantly influenced by the absence of prior year's non-recurring impairment loss, representing improved earnings quality from recurring operations.
Automotive (Core Business): Revenue 520.6 billion yen (+21.8 billion yen, +4.4%), Operating Income 29.3 billion yen (+15.3 billion yen, +109.3%). This segment represents the company's largest profit contributor with 23.0% of total operating income and drove overall profitability improvement. The substantial operating income growth was achieved through improved product mix toward high value-added products, successful pricing policy implementation, and cost optimization initiatives. Operating margin expanded significantly to approximately 5.6% from 2.8% in prior year. The segment achieved ROCE exceeding 10%, demonstrating strong capital efficiency relative to company average.
Chemicals: Revenue 584.2 billion yen (-9.4 billion yen, -1.6%), Operating Income 53.0 billion yen (-3.7 billion yen, -6.5%). Operating margin of 9.1% remained healthy though declined from 9.6% prior year. Performance Chemicals business showed volume growth, but Integrated Chemicals faced headwinds from lower PVC resin market prices in Southeast Asia and increased maintenance costs. Operating margin remains the highest among segments, reflecting mature business model with established market positions.
Electronics: Revenue 355.1 billion yen (-9.5 billion yen, -2.6%), Operating Income 47.5 billion yen (-6.9 billion yen, -12.7%). Operating margin compressed to 13.4% from 15.7% prior year. The decline was driven by reduced shipments of high-margin EUV photomask blanks for semiconductor manufacturing and one-time costs related to withdrawal from chemically strengthened specialty glass business. Display glass shipments increased, but could not fully offset the decline in electronic materials. The segment maintains the highest operating margin across all businesses despite the compression.
Architectural Glass: Revenue 441.1 billion yen (+3.2 billion yen, +0.7%), Operating Income 17.3 billion yen (+0.9 billion yen, +5.5%). Operating margin improved slightly to 3.9% from 3.7%. Pricing policy effects in Europe and Americas offset price declines in Asia and labor cost increases. The segment showed resilience despite continued weak economic conditions in Europe and China.
Life Sciences: Revenue 133.1 billion yen (-8.1 billion yen, -5.7%), Operating Loss -22.3 billion yen (loss widened by 1.1 billion yen). The segment remained unprofitable with operating margin of -16.8%. Synthetic pharmaceutical and agrochemical CDMO business performed steadily, but absence of prior year bio-pharmaceutical one-time income and increased fixed costs from European mammalian cell culture capacity expansion weighed on results. Management expects significant improvement in FY2026 as new CDMO capacity begins full operation.
The Automotive segment served as the primary driver of overall profit growth, while Life Sciences recovery from large-scale losses remains a key focus area for achieving company-wide profitability targets.
Profitability: ROE 4.7% (prior year -4.4%, improved from negative to positive), Operating Margin 6.2% (prior year 6.1%, essentially flat). ROE recovery was driven by return to net profitability, though the 4.7% level remains below the company's stated cost of equity of approximately 8%. Operating margin stability at 6.2% demonstrates consistent operational execution despite revenue headwinds.
Cash Quality: Operating CF to Net Income ratio 3.97x (operating CF 274.5 billion yen vs net income 69.2 billion yen), indicating strong cash-backed earnings quality well above the 1.0x threshold. Free Cash Flow 96.1 billion yen (operating CF 274.5 billion yen minus capex 209.5 billion yen adjusted basis) demonstrates solid cash generation after growth investments.
Investment: Capex to Depreciation ratio 1.40x (capex 251.3 billion yen vs depreciation & amortization 179.4 billion yen from PDF data), indicating continued growth phase investment though moderating from peak levels. Company plans to reduce capex to 190.0 billion yen in FY2026, shifting focus from capacity expansion to investment efficiency.
Financial Health: Equity Ratio 50.3% (prior year 49.4%), Current Ratio data incomplete but operating cash flow strength indicates adequate liquidity. Debt-to-Equity ratio 0.37 maintains conservative financial leverage. Net Debt to EBITDA approximately 2.1x indicates manageable debt burden.
Capital Efficiency: ROIC approximately 4.7% (calculation based on NOPAT/invested capital), below company target of 10% ROCE company-wide. Inventory turnover 109 days indicates room for working capital optimization. Total Asset Turnover 0.70x reflects capital-intensive business model characteristics.
Operating CF: 274.5 billion yen, representing 3.97x of Net Income (69.2 billion yen). The ratio well exceeds 1.0x threshold, indicating strong cash-backed earnings with high quality. The substantial operating cash generation reflects solid core business cash conversion despite modest net income levels, supported by depreciation add-backs and working capital management.
Investing CF: -178.4 billion yen, primarily consisting of capex 209.5 billion yen for capacity expansion projects including Southeast Asian chlor-alkali expansion, fluorochemical production enhancement, electronic materials manufacturing equipment, and bio-pharmaceutical/synthetic pharmaceutical CDMO capacity. Proceeds from asset sales and business divestitures partially offset capital expenditures, reflecting portfolio optimization efforts.
Financing CF: -73.6 billion yen, including dividend payments 44.6 billion yen, debt repayments, and minimal share buyback activity. The financing cash outflow reflects disciplined capital allocation with priority on maintaining stable dividends while reducing financial leverage.
FCF: 96.1 billion yen (Operating CF 274.5 billion yen minus investing capex, adjusted basis). Positive free cash flow demonstrates ability to fund both growth investments and shareholder returns from operating cash generation. FCF coverage of dividends at 2.10x provides comfortable cushion for dividend sustainability.
Cash generation: Strong. Operating cash flow significantly exceeds net income, demonstrating high-quality earnings backed by actual cash generation. The company maintains adequate liquidity with 94.7 billion yen in cash and cash equivalents, supported by consistent operating cash generation of 274.5 billion yen annually. Working capital efficiency remains an area for improvement given inventory days of 109, but overall cash generation capability is robust and supports both ongoing operations and strategic investments.
Ordinary vs Net Income: Ordinary income of 120.9 billion yen compared to net income attributable to owners of 69.2 billion yen shows a gap of 51.7 billion yen, primarily attributable to tax expenses (effective tax rate approximately 36.3% based on tax burden coefficient of 0.554) and minority interests. The prior year comparison is particularly significant - FY2024 recorded a massive loss of -77.9 billion yen due to a large-scale impairment loss of approximately 124.8 billion yen in the Life Sciences segment related to bio-pharmaceutical business assets. The absence of this non-recurring impairment in FY2025 represents a significant improvement in earnings quality, with FY2025 results reflecting more normalized recurring earning power.
Non-operating Income Composition: The improvement in ordinary income (+28.2%) significantly outpaced operating income growth (+1.3%), indicating material contribution from non-operating items. Financial income improved and other income/expenses showed favorable trends compared to prior year. However, these items remained relatively modest compared to revenue scale (non-operating net impact approximately 0.3% of revenue), falling below the 5% materiality threshold that would warrant detailed disclosure concern.
Accruals Assessment: Operating CF of 274.5 billion yen substantially exceeds Net Income of 69.2 billion yen, yielding a positive ratio of 3.97x. This indicates minimal accrual-based earnings inflation and suggests that reported earnings are solidly backed by actual cash generation. The accrual ratio of -7.0% from supplementary analysis confirms high earnings quality without concerning earnings management signals. The large positive gap between cash and accrual earnings primarily reflects substantial depreciation and amortization charges (179.4 billion yen) inherent to the capital-intensive manufacturing business model, rather than aggressive accounting practices.
Overall Assessment: Earnings quality improved significantly year-over-year with the elimination of prior year's large non-recurring impairment. FY2025 results reflect more sustainable recurring profitability backed by strong operating cash generation. The main quality consideration is the structural tax burden (36.3% effective rate) which creates a persistent gap between pre-tax and post-tax profitability, but this represents a recurring rather than earnings quality issue.
Full-year FY2026 Guidance: Revenue 2,200.0 billion yen (+141.2 billion yen, +6.9%), Operating Income 150.0 billion yen (+22.5 billion yen, +17.7%), Net Income 77.0 billion yen (+7.8 billion yen, +11.3%). The company projects acceleration in both revenue and operating income growth compared to FY2025 actual results.
Progress Assessment: FY2025 full year results represent 100% completion of the fiscal period, with actual operating income of 127.5 billion yen achieving 85.0% of the new FY2026 target of 150.0 billion yen. The FY2026 guidance implies significant year-over-year improvement across all profit metrics.
Key Drivers of FY2026 Outlook: Life Sciences segment expected to significantly narrow operating losses from -22.3 billion yen to -5.0 billion yen (+17.3 billion yen improvement) as synthetic pharmaceutical and agrochemical CDMO capacity expansions in North America and Europe begin full-scale commercial operation. Electronics segment anticipates recovery driven by increased shipments of EUV photomask blanks and other semiconductor-related materials as industry cycle improves. Chemicals segment expects contributions from Southeast Asian chlor-alkali capacity expansion reaching full operation and increased fluorochemical shipments. Automotive and Architectural Glass segments plan to maintain growth trajectory through continued pricing policy execution and product mix improvement. Foreign exchange assumptions of 155.0 yen/USD (vs 149.7 yen actual in FY2025) represent a 5.3 yen weaker yen, providing tailwind of approximately 2.7 billion yen to operating income.
Investment Phase Shift: Capital expenditure planned at 190.0 billion yen for FY2026, down from 251.3 billion yen (PDF basis) in FY2025, representing 24.4% reduction. Management characterizes this as transition from large-scale capacity expansion phase to harvesting phase with focus on investment efficiency and return generation from completed projects. The capex reduction is expected to enhance free cash flow generation while maintaining strategic growth investments.
Long-term Targets: Management maintains commitment to achieving ROE exceeding 8% (above estimated cost of equity) in early FY2027 or beyond, with intermediate target of ROE 5% or higher in FY2026 (guidance implies 5.2% based on projected net income and equity base). Company-wide ROCE target of 10% (equivalent to ROE 8%) remains in place, requiring operating profit improvement and optimization of operating assets across all segments.
The FY2026 guidance represents material improvement from FY2025 results and implies management confidence in Life Sciences recovery trajectory and Electronics cycle improvement as primary growth drivers.
Dividend Policy: Annual dividend 210 yen per share for both FY2025 (actual) and FY2026 (planned), consisting of interim dividend 105 yen and year-end dividend 105 yen. The company maintains a stable dividend policy with guideline DOE (Dividend on Equity) of approximately 3%, prioritizing dividend stability over strict payout ratio targeting.
Payout Ratio: FY2025 dividend payout ratio approximately 66.0% based on net income attributable to owners of 69.2 billion yen (calculation: 210 yen annual dividend divided by basic EPS 326.20 yen from XBRL data, though PDF guidance shows 318 yen EPS suggesting approximately 66% ratio). This represents an elevated payout ratio relative to typical corporate norms, reflecting management's commitment to stable dividends despite modest profitability levels. For FY2026, projected EPS of 363.12 yen (guidance) with planned dividend of 210 yen implies payout ratio declining to approximately 57.8%, providing improved sustainability as earnings grow.
Free Cash Flow Coverage: FCF of 96.1 billion yen covers dividend payments of 44.6 billion yen by 2.10x, indicating solid dividend sustainability from operating cash generation. Even with elevated payout ratios on net income basis, the strong operating cash flow generation (274.5 billion yen, 3.97x net income) provides substantial cushion for dividend payments.
Share Buyback: Share buyback activity was minimal in FY2025 with only limited treasury stock acquisition for employee stock compensation purposes. Management indicates share buyback decisions will be made comprehensively considering cash flow, investment opportunities, and market conditions, but does not provide specific buyback guidance for FY2026.
Total Return Ratio: With minimal buyback activity, total shareholder return ratio approximates the dividend payout ratio of approximately 66% for FY2025. Management's capital allocation priority emphasizes dividend stability, strategic growth investments (though moderating capex to 190 billion yen in FY2026), and financial health maintenance.
Sustainability Assessment: Dividend sustainability appears adequate based on strong operating cash flow generation and planned improvement in payout ratio to approximately 58% in FY2026 as earnings grow. The combination of FCF coverage at 2.10x and operating CF/Net Income ratio of 3.97x provides comfortable cushion. However, the relatively high payout ratio does limit flexibility for accelerating growth investments or responding to unexpected business headwinds. Management's stable dividend policy with DOE guideline of approximately 3% suggests commitment to maintaining 210 yen annual dividend as a floor while allowing payout ratio to decline naturally as earnings improve toward ROE 8% target.
Near-term: FY2026 Life Sciences segment loss narrowing by approximately 17 billion yen as North American and European synthetic pharmaceutical and agrochemical CDMO capacity expansions reach full commercial operation in first half 2026. Electronics segment recovery driven by semiconductor industry cycle improvement, particularly increased EUV photomask blanks demand and packaging-related materials shipments in second half 2026. Chemicals segment Southeast Asian chlor-alkali capacity expansion reaching full operation, contributing incremental volume and improved fixed cost absorption through 2026. Automotive segment sustained profitability improvement through continued product mix enhancement toward high value-added products and pricing policy execution despite potential automotive production volume headwinds.
Long-term: Achievement of company-wide ROCE 10% target (ROE 8% equivalent) by early FY2027 or beyond through operating profit improvement across all segments and optimization of operating assets including inventory reduction and selective business exits. Structural improvement in Life Sciences segment profitability as mammalian cell culture CDMO business scales with expanded customer base and improved operational efficiency, targeting return to profitability. Expansion in semiconductor-related materials portfolio across front-end to back-end processes, capturing growth in advanced packaging and heterogeneous integration technologies. Governance enhancement through transition to company with audit and supervisory committee structure in March 2026, establishing board with majority outside directors to strengthen oversight function. Portfolio optimization through continued evaluation of business unit performance against ROCE hurdles and strategic fit, with potential for additional divestitures or exits of underperforming assets to improve overall capital efficiency.
Industry Position (Reference - Proprietary Analysis):
Profitability: Operating Margin 6.2% (company 5-year range 6.0-6.5%), Net Profit Margin 3.9% (company 5-year range 3.5-4.3% excluding FY2024 loss). The company's operating margin has remained relatively stable in the lower-to-mid single digit range, reflecting the capital-intensive nature and competitive dynamics of the specialty glass and chemicals industries. ROE 4.7% (company 5-year average approximately 3-4% excluding extreme years) remains below management's stated cost of equity hurdle of approximately 8%, indicating ongoing need for capital efficiency improvement.
Growth: Revenue Growth -0.4% for FY2025 (company 5-year average approximately -0.5% to 0%), reflecting mature market exposure and cyclical demand patterns. The company has experienced relatively flat revenue trajectory over the medium term, with growth dependent on new capacity ramp-ups and product mix shifts rather than underlying market expansion.
Financial Health: Equity Ratio 50.3% maintains conservative capital structure above 50% threshold. Debt-to-Equity ratio 0.37 indicates disciplined financial leverage management well below typical manufacturing sector ranges of 0.8-1.2x.
Shareholder Returns: Dividend Payout Ratio 66.0% for FY2025 (company 5-year range 60-70% excluding loss years) reflects commitment to stable dividends despite modest profitability, with payout ratio elevated relative to typical industrial company ranges of 30-40% but justified by strong operating cash flow generation.
Note: Industry comparisons are based on proprietary analysis of publicly available earnings data across specialty materials, chemicals, and glass manufacturing sectors. The company's diversified segment structure spanning architectural glass, automotive glass, electronics materials, chemicals, and life sciences makes direct peer comparison challenging, as few companies compete across the identical portfolio breadth. Segment-specific metrics show wide dispersion, with Electronics achieving 13.4% operating margin while Architectural Glass operates at 3.9%, highlighting the importance of business mix in overall profitability assessment.
Life Sciences Segment Recovery Execution Risk: Life Sciences operating loss of -22.3 billion yen in FY2025 with planned improvement to -5.0 billion yen in FY2026 represents ambitious 17.3 billion yen turnaround dependent on successful commercial ramp-up of expanded mammalian cell culture CDMO capacity in Europe and North America. Delays in customer qualification, production yield issues, or slower-than-expected order intake could materially impact company-wide profitability targets. The segment has recorded cumulative losses exceeding 100 billion yen over recent years including prior year impairment of 124.8 billion yen, and sustained underperformance would jeopardize achievement of ROE 8% long-term target.
Working Capital Efficiency and Inventory Risk: Inventory turnover of 109 days (inventory 465.4 billion yen) represents elevated working capital intensity with approximately 22.6% of annual revenue tied up in inventory. The analysis flags quality alerts regarding potential excess inventory exposure. In capital-intensive manufacturing businesses with long production cycles, inventory obsolescence risk exists particularly in Electronics materials where technology transitions can rapidly shift demand. Failure to improve working capital efficiency would constrain free cash flow generation and limit financial flexibility for growth investments or enhanced shareholder returns.
Capital Efficiency and Return on Invested Capital: ROIC of approximately 4.7% significantly trails company target of 10% ROCE and cost of capital estimated at 8%. Despite planned capex reduction to 190 billion yen in FY2026 from 251.3 billion yen in FY2025, the company has invested cumulative capex exceeding 1 trillion yen over recent years in capacity expansions that have yet to generate target returns. Structural profitability in certain segments (Architectural Glass 3.9% margin, Life Sciences losses) and high effective tax rate of 36.3% create persistent headwinds to achieving hurdle rates. Extended period of below-cost-of-capital returns would erode shareholder value and potentially require portfolio restructuring including business exits or asset impairments. The FY2026 guidance implies ROIC improvement but still likely below 6%, indicating multi-year journey required to reach 10% target with execution risk across multiple initiatives.
Return to Profitability with Quality Concerns Remaining: The company achieved net income of 69.2 billion yen in FY2025, recovering from prior year loss of -77.9 billion yen, primarily through absence of Life Sciences impairment loss. However, ROE of 4.7% and ROIC of approximately 4.7% remain substantially below management's stated cost of equity hurdle of approximately 8% and target ROCE of 10%. Operating cash flow generation of 274.5 billion yen (3.97x net income) demonstrates strong core business cash conversion, but capital efficiency metrics indicate that the company generates returns below the cost of capital on its substantial asset base of 2,950 billion yen. The FY2026 guidance targeting ROE of approximately 5.2% shows improvement trajectory but highlights that achieving management's ROE 8% goal by early FY2027 requires sustained execution across multiple operating and capital efficiency initiatives. Investors should monitor quarterly progress on Life Sciences turnaround and operating asset optimization as key milestones toward acceptable return on equity.
Transition from Investment Cycle to Harvesting Phase: Planned reduction in capital expenditure from 251.3 billion yen in FY2025 to 190.0 billion yen in FY2026 (24.4% decrease) marks strategic shift from capacity expansion to investment efficiency focus. The company has completed major projects including Southeast Asian chlor-alkali expansion, Life Sciences CDMO capacity build-out, and Electronics materials manufacturing enhancements. FY2026 and beyond represent critical period for demonstrating return generation from these investments, with Life Sciences segment improvement of 17.3 billion yen and Electronics recovery serving as key proof points. The moderated capex level of 190 billion yen (approximately 1.06x depreciation of 179.4 billion yen) suggests maintenance-plus-selective-growth spending that should enhance free cash flow generation. This positions the company to potentially increase shareholder returns through combination of growing dividends as payout ratio declines from 66% toward 50% range and possible share buybacks if free cash flow exceeds 150-200 billion yen range in FY2026-2027. The investment phase transition represents both opportunity (improved cash returns) and risk (execution on return generation from completed projects).
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI analysis of PDF earnings presentation
AGC Inc.’s fiscal year ending December 2025 results showed net sales of 2,058.8 billion yen (flat YoY) and operating profit of 127.5 billion yen (+1.6 billion yen), a slight increase in earnings. Profit improvement in Automotive contributed, with profit attributable to owners of parent improving significantly to 69.2 billion yen. ROE improved to 4.7% but remained below the 8% target. For the fiscal year ending December 2026, recovery in Life Science is expected to drive growth, with operating profit of 150.0 billion yen and ROE of 5.2% forecast. The company aims for ROCE of 10% across all businesses (equivalent to ROE of 8%), promoting operating profit enhancement and optimization of operating assets. Capital expenditures will see the large-scale expansion phase largely conclude in 2025, with a policy to scale back investment from 2026 onward and focus on investment recovery.
Operating profit for the fiscal year ending December 2025 was 127.5 billion yen, missing the initial plan for the fourth consecutive year but increasing YoY. Automotive achieved ROCE above 10%, and Display saw benefits from profitability improvement measures materialize. Essential Chemicals Southeast Asia remained sluggish; Life Science continues to post losses but targets a return to profitability from 2027 onward. For the fiscal year ending December 2026, operating profit is forecast at 150.0 billion yen with ROE of 5.2%, aiming to exceed ROE of 8%—above the cost of equity—at an early stage from 2027 onward. Transition to a Company with an Audit and Supervisory Committee and a majority of outside directors to further deepen corporate governance.
In 2026, recovery in Life Science will drive an increase in operating profit. The global economy will grow moderately, but a challenging market environment will persist with continued stagnation in the European and Chinese economies and softer automobile production volumes. The semiconductor market will grow, led by AI-related demand, and the biologics CDMO market will recover gradually. Pricing initiatives, higher value-added offerings, and cost reductions will be pursued across all businesses, aiming to exceed ROE of 8% at an early stage from 2027 onward.
Outlook for the fiscal year ending December 2026: net sales of 2,200.0 billion yen, operating profit of 150.0 billion yen, profit attributable to owners of parent of 77.0 billion yen, and ROE of 5.2%. FX assumptions: USD/JPY 155, EUR/JPY 180; crude oil 70 dollars/barrel. The annual dividend will be maintained at 210 yen, with stable dividends guided by DOE of around 3%. Target ROCE of 10% across all businesses by boosting operating profit and optimizing operating assets. From 2026 onward, capital expenditures will be significantly curtailed to focus on investment recovery.
Promote ROCE improvement measures across all businesses: pricing initiatives, higher value-added offerings, cost reductions, disciplined investment selection, inventory reduction, and business divestitures/withdrawals. In Electronics, focus on advancing high functionality in Optoelectronics and developing/expanding sales in cutting-edge fields for semiconductor-related materials. In Integrated Chemicals, optimize the entire chemical chain centered on Performance Chemicals, focusing on three domains: Electronics, Energy, and Mobility. In Automotive, pursue pricing initiatives, business structure reforms, and continued shift to high-performance/high value-added products, targeting ROCE of 15% within several years. In Life Science, strengthen sales and marketing to expand orders for animal cell projects, stabilize production, and reduce costs to achieve profitability from 2027 onward.
Prolonged economic stagnation in Europe leading to weak demand for architectural glass and automotive. Continued economic stagnation in China keeping PVC and caustic soda market prices in Essential Chemicals Southeast Asia at low levels. Automobile production volumes trend softer, reducing automotive shipments. Continued slump in PVC resin and caustic soda market prices in Southeast Asia delays profitability improvement in Essential Chemicals Southeast Asia. Order expansion for animal cell projects in the Life Science biologics CDMO does not progress as planned, delaying the return to profitability.